Walleye Trading
GALT icon

Walleye Trading’s Galectin Therapeutics GALT Stock Holding History

Walleye Trading’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,600
Closed -$2K – 5029
2016
Q2 		$2K Buy
1,600
+100
+7% +$147 ﹤0.01% 5111
2016
Q1 		$2K Buy
1,500
+200
+15% +$269 ﹤0.01% 5109
2015
Q4 		$2K Buy
+1,300
New +$2.98K ﹤0.01% 5085

Other funds holding GALT

DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Walleye Trading's GALT Position: Q3 2016 in Review

Walleye Trading sold out of Galectin Therapeutics (GALT) in Q3 2016, closing a stake of 1,600 shares — an estimated $2K sold.

Walleye Trading first reported a position in GALT in Q4 2015 and held it in 3 quarters. The position peaked at $2K in Q2 2016. 46 funds tracked by Wall St. Rank hold GALT as of Q3 2016.

  • Walleye Trading reported no remaining Galectin Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Walleye Trading sold 1,600 Galectin Therapeutics shares in Q3 2016, an estimated $2K.
  • Walleye Trading first reported a position in Galectin Therapeutics in Q4 2015 and held it in 3 quarters.
  • Walleye Trading's Galectin Therapeutics position peaked at $2K in Q2 2016.
  • 46 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2016.

Based on Walleye Trading's 13F filing for Q3 2016, filed 14 Nov 2016.